Effect of dutasteride on castration‑resistant prostate cancer

Azuma,Takeshi; Matayoshi,Yukihide; Sato,Yujiro; Nagase,Yasuhi

doi:10.3892/mco.2017.1480

Effect of dutasteride on castration‑resistant prostate cancer

Authors:
- Takeshi Azuma
- Yukihide Matayoshi
- Yujiro Sato
- Yasuhi Nagase
View Affiliations

Affiliations: Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo 183‑0042, Japan
Published online on: November 2, 2017 https://doi.org/10.3892/mco.2017.1480
Pages: 133-136

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has previously been demonstrated that the intratumoral generation of the potent androgen dihydrotestosterone (DHT), contributes critically to the progression of prostate cancer and its castration‑resistant form, castration‑resistant prostate cancer (CRPC). Circulating testosterone is converted into DHT by 5α‑reductase (SRD5A). Dutasteride is a dual inhibitor of type I and II SRD5A. The present study assessed the effectiveness of dutasteride in the treatment of CRPC. Between 2010 and 2013, CRPC was diagnosed in 41 patients at the Tokyo Metropolitan Tama Medical Center. Following diagnosis, the patients received 0.5 mg dutasteride daily. The patients' median age was 77.3 years (range, 63‑90). Bone metastases were recognized in 12 patients. All the patients received dexamethasone. Twenty-four (59%) patients had previously undergone chemotherapy, while 11 (27%) received docetaxel, and 24 (59%) estramustine. The prostatic‑specific antigen (PSA) level declined in 17 (41%) patients from the baseline value, following dutasteride treatment. The median value for the PSA decrease was 23% (range, 4.3‑89.8%), and the median duration of the response was 4 months (range, 1‑10). The PSA response rate (defined as >50% decline in PSA from the baseline value) was recognized in 7 (17%) patients. The median duration of the response was 3 months (range, 2‑10). Dutasteride was efficacious against CRPC in certain patients and may be a promising option in CRPC treatment. A prospective randomized trial is necessary to verify the efficacy of dutasteride.

View Figures

View References

1	Marech I, Vacca A, Ranieri G, Gnoni A and Dammacco F: Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int J Oncol. 40:1313–1320. 2012.PubMed/NCBI
2	Nacusi LP and Tindall DJ: Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol. 8:378–384. 2011. View Article : Google Scholar : PubMed/NCBI
3	Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68:6407–6415. 2008. View Article : Google Scholar : PubMed/NCBI
4	Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
5	Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66:2815–2825. 2006. View Article : Google Scholar : PubMed/NCBI
6	Geller J, Albert JD, Nachtsheim DA and Loza D: Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol. 132:693–696. 1984. View Article : Google Scholar : PubMed/NCBI
7	Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res. 10:440–448. 2004. View Article : Google Scholar : PubMed/NCBI
8	Titus MA, Schell MJ, Lih FB, Tomer KB and Mohler JL: Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 11:4653–4657. 2005. View Article : Google Scholar : PubMed/NCBI
9	Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67:5033–5041. 2007. View Article : Google Scholar : PubMed/NCBI
10	Gleave ME, La Bianca S and Goldenberg SL: Neoadjuvant hormonal therapy prior to radical prostatectomy: Promises and pitfalls. Prostate Cancer Prostatic Dis. 3:136–144. 2000. View Article : Google Scholar : PubMed/NCBI
11	Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
12	Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
13	Yin L and Hu Q: CYP17 inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat Rev Urol. 11:32–42. 2014. View Article : Google Scholar : PubMed/NCBI
14	Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y and Nakagawa H: Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 99:81–86. 2008.PubMed/NCBI
15	Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ and Sharifi N: Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA. 108:pp. 13728–13733. 2011; View Article : Google Scholar : PubMed/NCBI
16	Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 362:1192–1202. 2010. View Article : Google Scholar : PubMed/NCBI
17	Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S and van Vierssen Trip OB: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 44:461–466. 2003. View Article : Google Scholar : PubMed/NCBI
18	Tindall DJ and Rittmaster RS: The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 179:1235–1242. 2008. View Article : Google Scholar : PubMed/NCBI
19	Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 17:958–967. 1999. View Article : Google Scholar : PubMed/NCBI
20	Sella A, Sternberg CN, Skoneczna I and Kovel S: Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int. 102:1607–1609. 2008. View Article : Google Scholar : PubMed/NCBI
21	Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP and Oh WK: Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 7:E90–E92. 2009. View Article : Google Scholar : PubMed/NCBI